A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD)

• Status: NOT_YET_RECRUITING
• Trial end date: 2027-03-31

Summary

The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

• Phase: PHASE4

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel
• Treatments: Budesonide; Metered Dose Inhalers